Mid-cap stocks are proving to be an attractive investment option over the past few years.

5 Best and Worst Performing Mid-Cap Stocks in Q4 2022

Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.

These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022

Immunovant is developing a similar drug to argenx, but at 10% of argenx's valuation, offering a good option value and a hedge against owning argenx. Immunovant has a new generation anti-FcRn IMVT-1402, and recent pre-clinical data showed that it does not impact albumin levels (which was the key overhang for batoclimab).

Immunovant: argenx At A 10% Valuation, Initiating With A Buy Rating

Here are four drug companies, MRK, VRTX, IMCR and IMVT, that are up 40% or more in 2022 so far and still have room for growth in 2023.

4 Drug Stocks Up More Than 40% YTD With Room to Grow in 2023

Here is how Immunovant, Inc. (IMVT) and McKesson (MCK) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Immunovant (IMVT) This Year?

Immunovant (IMVT) is progressing well with its lead pipeline candidate batoclimab being developed for treating myasthenia gravis, thyroid eye disease and other autoimmune diseases.

Reasons to Add Immunovant (IMVT) Stock to Your Portfolio Now

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.